# DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

> **NCT06757244** · PHASE2 · RECRUITING · sponsor: **Hopital Foch** · enrollment: 35 (estimated)

## Conditions studied

- Pancreas Neoplasms

## Interventions

- **DRUG:** Dostarlimab
- **DRUG:** Vitamin D3 (Cholecalciferol)
- **DRUG:** mFOLFIRINOX Treatment Regimen
- **DRUG:** LV5FU2

## Key facts

- **NCT ID:** NCT06757244
- **Lead sponsor:** Hopital Foch
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2028-02-18
- **Final completion:** 2028-02-18
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06757244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06757244, "DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06757244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*